A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
JOURNEY
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
1 other identifier
interventional
990
22 countries
268
Brief Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2025
Typical duration for phase_3
268 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 3, 2025
CompletedFirst Posted
Study publicly available on registry
March 14, 2025
CompletedStudy Start
First participant enrolled
March 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 13, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 5, 2029
April 13, 2026
April 1, 2026
4 years
March 3, 2025
April 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Annualised rate of moderate or severe COPD exacerbations
The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo.
Baseline up to 76 weeks
Secondary Outcomes (13)
Change from baseline in post-BD FEV1
From baseline to Week 52
Change from baseline in pre-dose/pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)
From baseline to Week 52
Change from baseline in the St. George's Respiratory Questionnaire (SGRQ) total score
From baseline over 52 weeks
Annualised rate of moderate or severe COPD exacerbations among participants with EOS ≥ 300 cells/µL collected during screening visit.
Baseline up to 76 weeks
Annualised rate of severe COPD exacerbations
Baseline up to 76 weeks
- +8 more secondary outcomes
Study Arms (3)
Dose 1 of Tezepelumab
EXPERIMENTALTezepelumab, SC, Q4W
Dose 2 of Tezepelumab
EXPERIMENTALTezepelumab, SC, Q4W
Matching Placebo
PLACEBO COMPARATORMatching placebo, SC, Q4W
Interventions
Eligibility Criteria
You may qualify if:
- ≥40 to ≤80 years old
- COPD diagnosis ≥1 year,
- Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC \<0.70 at screening
- Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1
- ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy
- EOS ≥ 150 cells/μL during screening
- CAT ≥15 at screening
- Former or current smokers ≥10 pack-years
You may not qualify if:
- Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD
- Asthma, incl. pediatric, or ACOS
- Any unstable disorder that can impact participants safety or study outcomes
- Tuberculosis requiring treatment within 12 months prior V2
- Malignancies current or past
- Concomitant therapies:
- Macrolides (less than 6 months)
- Systemic immuno-suppressive, -modulating medications
- LTOT \>4.0 L/min or O2 saturation \<89% despite LTOT
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Amgencollaborator
Study Sites (268)
Research Site
Cullman, Alabama, 35055, United States
Research Site
Phoenix, Arizona, 85044, United States
Research Site
Scottsdale, Arizona, 85258, United States
Research Site
Inglewood, California, 90301, United States
Research Site
Los Angeles, California, 90048, United States
Research Site
Palo Alto, California, 94304, United States
Research Site
Redding, California, 96001, United States
Research Site
San Diego, California, 92108, United States
Research Site
New Britain, Connecticut, 06051, United States
Research Site
Wilmington, Delaware, 19803, United States
Research Site
Bay Pines, Florida, 33744, United States
Research Site
Boynton Beach, Florida, 33435, United States
Research Site
Clearwater, Florida, 33765, United States
Research Site
Fleming Island, Florida, 32003, United States
Research Site
Jacksonville, Florida, 32209, United States
Research Site
Leesburg, Florida, 34748, United States
Research Site
Margate, Florida, 33063, United States
Research Site
Miami, Florida, 33126, United States
Research Site
Miami, Florida, 33155, United States
Research Site
Miami Lakes, Florida, 33014, United States
Research Site
Ocala, Florida, 34470, United States
Research Site
Palmetto Bay, Florida, 33157, United States
Research Site
Winter Park, Florida, 32789, United States
Research Site
Adairsville, Georgia, 30103, United States
Research Site
Atlanta, Georgia, 30349, United States
Research Site
Cordele, Georgia, 31015, United States
Research Site
Decatur, Georgia, 30033, United States
Research Site
Fort Eisenhower, Georgia, 30905, United States
Research Site
Savannah, Georgia, 31406, United States
Research Site
Evanston, Illinois, 60201, United States
Research Site
Evansville, Indiana, 47725, United States
Research Site
Indianapolis, Indiana, 46202, United States
Research Site
Indianapolis, Indiana, 46268, United States
Research Site
Kansas City, Kansas, 66160, United States
Research Site
Bowling Green, Kentucky, 42101, United States
Research Site
Owensboro, Kentucky, 42301, United States
Research Site
Baltimore, Maryland, 21224, United States
Research Site
Potomac, Maryland, 20854, United States
Research Site
Ann Arbor, Michigan, 48109, United States
Research Site
Minneapolis, Minnesota, 55425, United States
Research Site
Hannibal, Missouri, 63401, United States
Research Site
Staten Island, New York, 10309, United States
Research Site
Syracuse, New York, 13203, United States
Research Site
Charlotte, North Carolina, 28277, United States
Research Site
Fayetteville, North Carolina, 28303, United States
Research Site
Oklahoma City, Oklahoma, 73102, United States
Research Site
Tulsa, Oklahoma, 74133, United States
Research Site
Grants Pass, Oregon, 97527, United States
Research Site
Sayre, Pennsylvania, 18840, United States
Research Site
Anderson, South Carolina, 29621, United States
Research Site
Columbia, South Carolina, 29204, United States
Research Site
Gaffney, South Carolina, 29340, United States
Research Site
Spartanburg, South Carolina, 29303, United States
Research Site
Union, South Carolina, 29379, United States
Research Site
Rapid City, South Dakota, 57702, United States
Research Site
Knoxville, Tennessee, 37919, United States
Research Site
Boerne, Texas, 78006, United States
Research Site
El Paso, Texas, 79902, United States
Research Site
Houston, Texas, 77008, United States
Research Site
Houston, Texas, 77074, United States
Research Site
Houston, Texas, 77094, United States
Research Site
Lewisville, Texas, 75067, United States
Research Site
McKinney, Texas, 75069, United States
Research Site
Mesquite, Texas, 75149, United States
Research Site
San Antonio, Texas, 78258, United States
Research Site
Colchester, Vermont, 05446, United States
Research Site
Williamsburg, Virginia, 23188, United States
Research Site
Everett, Washington, 98208, United States
Research Site
Alberdi, X5033DCE, Argentina
Research Site
Buenos Aires, C1425BEN, Argentina
Research Site
Ciudad de Buenos Aires, C1414AIF, Argentina
Research Site
Florida, B1602DQD, Argentina
Research Site
La Plata, B1900, Argentina
Research Site
La Plata, B1904, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Mendoza, M5500CCG, Argentina
Research Site
Quilmes, B1878FNR, Argentina
Research Site
Rosario, 2000, Argentina
Research Site
San Fernando, B1646EBJ, Argentina
Research Site
San Juan Bautista, 1888, Argentina
Research Site
Coffs Harbour, 02450, Australia
Research Site
Frankston, 3199, Australia
Research Site
Garran, 2605, Australia
Research Site
Nedlands, 6009, Australia
Research Site
New Lambton, 2310, Australia
Research Site
Spearwood, 6163, Australia
Research Site
Wollongong, 2500, Australia
Research Site
Woodville South, 5011, Australia
Research Site
Genk, 3600, Belgium
Research Site
Ghent, 9000, Belgium
Research Site
Jette, 1090, Belgium
Research Site
Leuven, 3000, Belgium
Research Site
Mechelen, 2800, Belgium
Research Site
Namur, 5101, Belgium
Research Site
Dupnitsa, 2600, Bulgaria
Research Site
Haskovo, 6300, Bulgaria
Research Site
Lovech, 5500, Bulgaria
Research Site
Pleven, 5800, Bulgaria
Research Site
Plovdiv, 4003, Bulgaria
Research Site
Rousse, 7000, Bulgaria
Research Site
Rousse, 7000, Bulgaria
Research Site
Sofia, 1000, Bulgaria
Research Site
Sofia, 1202, Bulgaria
Research Site
Sofia, 1431, Bulgaria
Research Site
Sofia, 1756, Bulgaria
Research Site
Stara Zagora, 6003, Bulgaria
Research Site
Varna, 9000, Bulgaria
Research Site
Veliko Tanovo, 5000, Bulgaria
Research Site
Veliko Tarnovo, 5000, Bulgaria
Research Site
Vidin, 3700, Bulgaria
Research Site
Yambol, 8600, Bulgaria
Research Site
Armenia, 630004, Colombia
Research Site
Barranquilla, 080020, Colombia
Research Site
Bogotá, 110131, Colombia
Research Site
Cali, 760042, Colombia
Research Site
Ibagué, 730006, Colombia
Research Site
Manizales, 170004, Colombia
Research Site
Medellín, 050022, Colombia
Research Site
Medellín, 050030, Colombia
Research Site
Aalborg, 9000, Denmark
Research Site
Hvidovre, 2650, Denmark
Research Site
Næstved, 4700, Denmark
Research Site
Odense C, 5000, Denmark
Research Site
Vejle, 7100, Denmark
Research Site
Brest, 29609, France
Research Site
Lyon, 69317, France
Research Site
Marseille, 13915, France
Research Site
Montpellier, 34295, France
Research Site
Paris, 75014, France
Research Site
Paris, 75877, France
Research Site
Pessac, 33604, France
Research Site
Saint-Herblain, 44800, France
Research Site
Athens, 11521, Greece
Research Site
Athens, 11527, Greece
Research Site
Athens, 17562, Greece
Research Site
Heraklion, 71110, Greece
Research Site
Ioannina, 45500, Greece
Research Site
Pátrai, 26332, Greece
Research Site
Thessaloniki, 57001, Greece
Research Site
Thessaloniki, 57010, Greece
Research Site
Hong Kong, 999077, Hong Kong
Research Site
Hong Kong, Hong Kong
Research Site
Budapest, 1036, Hungary
Research Site
Debrecen, 4032, Hungary
Research Site
Edelény, 3780, Hungary
Research Site
Gödöllő, 2100, Hungary
Research Site
Hatvan, 3000, Hungary
Research Site
Mosonmagyaróvár, 9200, Hungary
Research Site
Nyíregyháza-Sóstóhegy, 4481, Hungary
Research Site
Törökbálint, 2045, Hungary
Research Site
Ashkelon, 78278, Israel
Research Site
Haifa, 34362, Israel
Research Site
Jerusalem, 00000, Israel
Research Site
Jerusalem, 90131, Israel
Research Site
Kfar Saba, 4428164, Israel
Research Site
Ramat Gan, 52621, Israel
Research Site
Rehovot, 76100, Israel
Research Site
Tel Aviv, 6423906, Israel
Research Site
Akashi-shi, 674-0063, Japan
Research Site
Chikushino-shi, 818-8502, Japan
Research Site
Chiyoda-ku, 1020074, Japan
Research Site
Fukui-shi, 910-8526, Japan
Research Site
Fukuoka, 811-1394, Japan
Research Site
Fukuoka, 819-8555, Japan
Research Site
Gifu, 502-8558, Japan
Research Site
Iruma-Gun, 350-0495, Japan
Research Site
Ishinomaki, 986-8522, Japan
Research Site
Kasuga-shi, 816-0864, Japan
Research Site
Kitakyushu-shi, 807-8555, Japan
Research Site
Kiyose-shi, 204-8522, Japan
Research Site
Kiyose-shi, 204-8585, Japan
Research Site
Kobe, 650-0047, Japan
Research Site
Komatsu-shi, 923-8560, Japan
Research Site
Kure-shi, 737-8505, Japan
Research Site
Kyoto, 612-8555, Japan
Research Site
Matsusaka-shi, 515-8544, Japan
Research Site
Meguro-ku, 153-0051, Japan
Research Site
Minatoku, 105-8470, Japan
Research Site
Minatoku, 108-0073, Japan
Research Site
Miyazaki, 889-1692, Japan
Research Site
Mizunami-shi, 509-6134, Japan
Research Site
Nagaoka-shi, 940-8621, Japan
Research Site
Nagasaki, 852-8501, Japan
Research Site
Nagoya, 457-0866, Japan
Research Site
Nagoya, 457-8511, Japan
Research Site
Nagoya, 466-8650, Japan
Research Site
Nerima-ku, 177-8521, Japan
Research Site
Ohta-ku, 143-0013, Japan
Research Site
Okayama, 700-8558, Japan
Research Site
Okayama, 701-1192, Japan
Research Site
Osaka, 540-0008, Japan
Research Site
Sapporo, 064-0804, Japan
Research Site
Sendai, 980-8574, Japan
Research Site
Sendai, 983-8520, Japan
Research Site
Shinjuku-ku, 160-8582, Japan
Research Site
Shinjuku-ku, 162-8655, Japan
Research Site
Shinjuku-ku, 162-8666, Japan
Research Site
Shiogama, 985-8506, Japan
Research Site
Takamatsu, 760-0018, Japan
Research Site
Takatsuiki-shi, 569-1096, Japan
Research Site
Tanabe-shi, 646-8558, Japan
Research Site
Toshima-ku, 171-0014, Japan
Research Site
Ube, 755-8505, Japan
Research Site
Yokohama, 236-0004, Japan
Research Site
Yokohama, 245-8575, Japan
Research Site
Eindhoven, 5623 EJ, Netherlands
Research Site
Maastricht, 6229 HX, Netherlands
Research Site
Rotterdam, 3045 PM, Netherlands
Research Site
Rotterdam, 3083 AN, Netherlands
Research Site
Zutphen, 7207 AE, Netherlands
Research Site
Auckland, 0626, New Zealand
Research Site
Auckland, 1051, New Zealand
Research Site
Auckland, 2025, New Zealand
Research Site
Hamilton West, 3204, New Zealand
Research Site
Tauranga, 3112, New Zealand
Research Site
Cusco, CUSCO 01, Peru
Research Site
Lima, 15036, Peru
Research Site
Lima, 15036, Peru
Research Site
Lima, 15046, Peru
Research Site
Lima, 15088, Peru
Research Site
Lima, LIMA 01, Peru
Research Site
Lima, LIMA 1, Peru
Research Site
Lima, LIMA 21, Peru
Research Site
Lima, LIMA 33, Peru
Research Site
Piura, 20001, Peru
Research Site
Bucharest, 011461, Romania
Research Site
Bucharest, 050159, Romania
Research Site
Cluj-Napoca, 400275, Romania
Research Site
Cluj-Napoca, 400332, Romania
Research Site
Oradea, 410176, Romania
Research Site
Timișoara, 300002, Romania
Research Site
Timișoara, 300310, Romania
Research Site
Bellville, 7530, South Africa
Research Site
Benoni, 1501, South Africa
Research Site
Cape Town, 7700, South Africa
Research Site
Durban, 4001, South Africa
Research Site
Durban, 4093, South Africa
Research Site
eMkhomazi, 4170, South Africa
Research Site
Kimberley, 8301, South Africa
Research Site
Somerset West, 7130, South Africa
Research Site
Gothenburg, 413 46, Sweden
Research Site
Karlskrona, 371 79, Sweden
Research Site
Lund, 22185, Sweden
Research Site
Örebro, 703 62, Sweden
Research Site
Stockholm, 11446, Sweden
Research Site
Stockholm, 171 64, Sweden
Research Site
Bang Kra So, 11000, Thailand
Research Site
Bangkok, 10330, Thailand
Research Site
Hat Yai, 90110, Thailand
Research Site
Muang, 22000, Thailand
Research Site
Muang, 40002, Thailand
Research Site
Mueang, 20000, Thailand
Research Site
Rayong, 21000, Thailand
Research Site
Adana, 1330, Turkey (Türkiye)
Research Site
Ankara, 6620, Turkey (Türkiye)
Research Site
Istanbul, 34020, Turkey (Türkiye)
Research Site
Kayseri, 38039, Turkey (Türkiye)
Research Site
Kocaeli, 41380, Turkey (Türkiye)
Research Site
Mersin, 33079, Turkey (Türkiye)
Research Site
Can Tho, 900000, Vietnam
Research Site
Da Nang, 550000, Vietnam
Research Site
Haiphong, 180000, Vietnam
Research Site
Hanoi, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Research Site
Hồ Chí Minh, 700000, Vietnam
Research Site
Huế, 530000, Vietnam
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
MeiLan Han, MD
University of Michigan Health, Pulmonary & Critical Care Medicine,
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Double-blinded
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 3, 2025
First Posted
March 14, 2025
Study Start
March 25, 2025
Primary Completion (Estimated)
March 13, 2029
Study Completion (Estimated)
June 5, 2029
Last Updated
April 13, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.